Oncolytic Viruses for Cancer Therapy in Dogs.
Level 5 - mechanism / opinion, no new human data
Systematic review of animal and veterinary preclinical/clinical studies
PubMed 42198720 · doi:10.3390/v18050518
What was done
This systematic review summarized preclinical and clinical studies evaluating various oncolytic virus platforms (including myxoma virus, reovirus, vesicular stomatitis virus, canine adenoviruses, vaccinia virus, Sendai virus, and Newcastle disease virus) for cancer treatment in domestic dogs.
What was found
The abstract reports no numerical data, effect sizes, or quantitative outcomes. Qualitatively, multiple oncolytic virus platforms demonstrated favorable tolerability and modest antitumor activity, while facing challenges related to pre-existing immunity, dosing optimization, and the need for rational combination strategies.
Why it matters
It provides a consolidated overview of oncolytic virotherapy in veterinary oncology, highlighting both therapeutic potential in dogs and translational implications for human cancer trials.
Limits
The abstract does not state the number of included studies or subjects, nor does it provide quantitative metrics. The synthesized data consist of animal/veterinary studies across heterogeneous tumor types and viral platforms.